This report provides comprehensive insights about LNP023 for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets. A detailed picture of the LNP023 for PNH in the 7MM, i.e., the United ...

Basel, August 29, 2020 — Novartis today announced new Phase II data for LNP023, an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the virtually held 2020 ...

Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual ...

Please provide your email address to receive an email when new articles are posted on . Paroxysmal nocturnal hemoglobinuria (PNH) is a rare but life-threatening blood disorder associated with ...

Novartis has presented midphase data showing paroxysmal nocturnal hemoglobinuria (PNH) patients can safely transition from Alexion’s Soliris to its experimental oral candidate LNP023. The open-label ...

C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1-3 Iptacopan (LNP023) is a potential first-in-class, oral, potent and ...

Please provide your email address to receive an email when new articles are posted on . Iptacopan was shown to safely reduce proteinuria in patients with C3 glomerulopathy after 12 weeks of treatment, ...

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria · ...

About LNP023 LNP023 is a first-in-class, orally administered, potent and highly selective factor B inhibitor of the alternative complement pathway. 3,4 LNP023 is currently in clinical development for ...